George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I did thank you metis
Thanks Kong1 - see my post at 11:05 today!!!
Metis the post i put up is doenloaded from the companys own RNS !!!!!!
Just googled it, didn’t realise I’d stumbled on your moniker Phantom!
Well he'd been going for a more conservative £3-£5 range recently, I thought we were big in trouble tbh
Speedboat, Phantom 25?
You’re kidding Mikey, JR has posted £50 a share at least once a day for months.
Jim, yeah, why not? I’ve ordered a speedboat and I’m getting the swimming pool measured up as I type.
Been a while since I last saw a £50 ramp, now I know we're in business
That’s correct Jim, a snip at $10.8Bn, and that company haven’t found the holy grail. Leeds Uni have, they’re called affimers and well, blow me down with a feather, it turns out Awacta own the IP
A 10.8B T/O would equate to over £50 per share which is no longer inconceivable as it was a couple of months ago. Patience required obviously.
Don’t let this beaut fall too far down the page
CautiousO lol yes I see. No it was a snippet from a personal conversation that I can't separate.
Ans gory end of front line.
CautiousO, interesting that the tweet referencing the above paper appeared just after the market closed, further I note that the author has quite happily expanded (when questioned) on the commercial/medical possibilities. It seems to be incredible work and I’m left feeling rather inadequate!
Onwards and upwards and GLA long term holders.
Kong1 it would be good to know where you found the following? -
"As previously announced, Avacta has entered into an exclusive global distribution agreement with Medusa19 Limited ("Medusa19") for direct-to-consumer sales of its newly developed saliva-based rapid test for the COVID-19 antigen, subject to regulatory approvals. "
As previously announced, Avacta has entered into an exclusive global distribution agreement with Medusa19 Limited ("Medusa19") for direct-to-consumer sales of its newly developed saliva-based rapid test for the COVID-19 antigen, subject to regulatory approvals. A short time prior to this the Company announced its partnership with Cytiva (formerly GE Healthcare Life Sciences) to develop an Affimer®-based point-of-care rapid antigen test (in the form of a simple test strip), to indicate whether a person has the COVID-19 infection. The test is intended to give a result within minutes and is for use by both healthcare professionals and consumers.
now how i`m looking into this, is that the company has made the test kits ! and proven it works !, and all they are waiting for is the regulartiry approval ?
Does everyone agree with this ?
if so, once announced, surely the sp should ramp up dramatically ?
Trek - Excellent post below, I think the fact the recent placing was so over subscribed, and SP has reached a good level is very telling!! I'm certain Alistair will want to have some news prior to Thursday's presentation, so wouldn't be suprised at all if an RNS lands in the run up to the presentation. With the reports of spikes of covid19 in some regions such as NW and SW, testing is the way forward. GL ALL!!
Wilson - is that your son’s technical explanation? Is he involved in biotech or marketing? ;)
Thanks Trek for the views... agree would like to have heard that pitch to the institutions! Here’s hoping we get a rerun of much the same content Thursday. Not sure if it is possible to be deeper than the proverbial balls, but if no news on Monday, I will investigate the possibility.
Reaches places normal drug applications cannot reach!!!!
Thanks TM for sharing great research your contributions greatly appreciated
"3. What’s the fallback if LFT fails... BAMS, Adeptrix etc and they’d give the revenue guidance, wow!"
If only two proteins involved then Adeptric could be ready soon !
“Development of a BAMS test capable of diagnosing whether a person has the COVID-19 infection at any specific moment is a quick process and the companies are aiming to have a BAMS test ready for clinical validation, regulatory approval and manufacturing in June. Adeptrix and Avacta are already in discussion with large-scale manufacturing partners to rapidly deploy this new high throughput test.”
11 May 2020 “The Affimer reagents have now been manufactured by Avacta in the quantities required for test development and are being sent to Cytiva today. The reagents are also being provided to Adeptrix with whom Avacta has announced that it will develop a COVID-19 laboratory test to run on hospital mass spectrometers using Adeptrix's proprietary BAMSTM assay platform.
Adeptrix provide info on website
“Custom BAMS Assay Development Timeline
Number of days involved depends on --Number of Test Samples - Number of Protein Targets
Anyway if you assume process for Adeptrix starts on receipt of reagents say 13th May at stage “iii. Assay configuration, formulate affinity beads”
Avacta mentioned June for manufacture which is possible as from Monday 8th June already 26 days have passed so could be anytime for news ?
See timetables in link below
https://adeptrix.com/custom-project
Great Post Trek.
That’s a couple of papers on Affimer use out now.
Imo AVCT would have needed to have made a massive pick to lock in £48m so soon after just coming to the market. There would be a couple of obvious questions.
1. Does the LFT work? Yes here’s the evidence of using Affimer tech to positively identify the Congo viral pathogen on a membrane. No blockages. The beads work. Obviously we cannot tell you how Cytiva are progressing but it works.
2. What’s this situation with customers. We are in discussion with xyz and we have Medusa B2C covered.
3. What’s the fallback if LFT fails... BAMS, Adeptrix etc and they’d give the revenue guidance, wow!
4 Affimer tech, they’d use the examples from Leeds Uni and any heads up with big Pharma...
That’s only scrapping the surface, not even mentioning what they want the money for but I think you get the gist. It would have to be a massive pitch from where we have come from and against a difficult market to raise risk money let alone for a biotech sector with a reputation for more collapses than success.
Well they not only got the money but also the discount was pretty good. What a story they must have told. I don’t know about you but the deal feels more accretive than dilutive and I think we will see the results of that £48m pitch next week.
I am biased as I added again Friday coz £48m on top of £18m says it works and that was enough of an indicator for me. I did not want to be refreshing an NT screen, dealing at best or sending trades to fill or kill when news hits but I do understand others risk appetites vary. There is gonna be a massive amount of money on the sidelines waiting for news!
Enjoy the ride!
Trek
Cautious Tks for posting.
Sent to my son for explanation
We have identified two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signalling pathways with distinct isoform and mutant profiles. Affimer K6 is the first biologic to bind in the SI/SII pocket, whilst Affimer K3 is the first non-covalent inhibitor of the SII region, revealing a novel RAS conformer with a large, druggable SII/a3 pocket. This work demonstrates the potential of using biologics with small interface surfaces to select novel druggable conformations in conjunction with pharmacophore identification for hard-to-drug proteins
A couple of snippets in plain English I liked...
‘could revolutionise drug discovery, exemplifying a novel pipeline for small molecule design that has the potential to unlock the vast number of currently ‘undruggable’ proteins.’
‘ The approach utilised in this study is likely to be applicable to other important therapeutic targets, and provides a novel pipeline for drug discovery.’
In a nutshell, affimers are disruptive tech, the small size means they can not only replace antibodies but are far superior. I’m not surprised the paper included disclaimers that some of them own Awacta shares! Tomlinson lab are having a field day with affimers, great stuff. Another candidate for a lot of bumping on the chat all day today, absolutely incredible discoveries. Let’s get this Covid thing out of the way and get cancer sorted!
Off Twitter, this account worth a follow:
https://twitter.com/tomlinson_lab/status/1268936665709633540?s=21
“Our latest paper is in preprint. Another example of how @affimers #AVCT can be used. Here we show the ability to identify druggable pockets on KRas, the ‘holy grail’ of cancer proteins.”
Holy grail, eh?
Great paper and another way our Affimers can be used by pharma.